Table 2 Main clinical outcomes
Diuretic aloneDiuretic + IrbesartanDiuretic + Ramiprilp Value
Readmission for HF (%)6 (12.2)6 (11.1)5 (11.4)
Cardiovascular death (weeks)1 (38)1 (51)0
Other cause of death2 (liver and lung cancer)00
Withdrawn (%)3 (6.0)3 (5.3)6 (13.3)
QoL score
Baseline20 (1.8)19 (2.1)23 (2.3)0.3
12 weeks12.9 (1.5)**10.8 (1.6)**12.7 (1.4)**0.9
24 weeks10. 9 (1.3)**9.6 (1.2)**12.9 (1.7)**0.8
52 weeks10.9 (1.3)**9.4 (1.3)**11.4 (1.4)**0.7
6MWT (feet/6 mins)
Baseline1011 (37)950 (37)962 (42)0.4
12 weeks1055 (38)988 (37)1011 (43)0.2
24 weeks1048 (43)1007 (33)1028 (37)0.8
Blood pressure (mean (SD)) (mm Hg)
Baseline145 (23)/80 (12)144 (19)/82 (10)143 (22)/82 (10)0.9
4 weeks139 (21)/77 (10)***134 (16)/76 (11)***138 (21)/77 (12)***0.3
8 weeks134 (18)/76 (13)***135 (18)/76 (11)***139 (20)/76 (11)***0.6
12 weeks134 (21)/75 (12)***136 (20)/76 (10)***136 (18)/77 (10)***0.9
24 weeks138 (17)/80 (9)***136 (20)/76 (12)**137 (21)/76 (11)0.5
52 weeks138 (24)/78 (10)137 (21)/73 (10)141 (23)/76 (13)0.7
NT-proBNP (mean (SD)) (pg/ml)
Baseline566 (944)568 (757)488 (701)0.7
12 weeks390 (625)394 (641)282 (376)1.0
52 weeks334 (414)443 (603)**314 (422)*0.52
  • Results expressed as mean (SEM) unless otherwise stated.

  • *p<0.05; **p<0.01; ***p<0.001 vs baseline.

  • NT-proBNP, N-terminal pro-brain natriuretic peptide; QoL, quality of life score; 6MWT, 6-minute corridor walk test.